Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)
Helen X. Chen(National Cancer Institute), Magdalena Thurin(Center for Cancer Research), Stephen M. Hewitt(National Institutes of Health), Stacey J. Adam(Foundation for the National Institutes of Health), Diane M. Del Valle(Icahn School of Medicine at Mount Sinai), Lyndsay N. Harris(University Hospitals Cleveland Medical Center), Elad Sharon(National Cancer Institute), Sylvie Janssens(Emmes (United States)), Robert R. Jenq(Anderson University - South Carolina), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Gheath Alatrash(The University of Texas MD Anderson Cancer Center), Valérie Tatard-Leitman(Emmes (United States)), David R. Patton(National Cancer Institute), Beatriz Sánchez‐Espiridión(The University of Texas MD Anderson Cancer Center), James H. Doroshow(National Cancer Institute), Srinika Ranasinghe(Dana-Farber Cancer Institute), Sean C. Bendall(Stanford University), Catherine J. Wu(Broad Institute), Xiaole Shirley Liu(The Synergetic Innovation Center for Advanced Materials), Chantale Bernatchez(The University of Texas MD Anderson Cancer Center), Minkyung Song(Cornell University), Jeffrey S. Abrams(National Cancer Institute), Radim Moravec(Center for Cancer Research), Margaret Mooney(National Cancer Institute), James Lindsay, Holden T. Maecker(Stanford University), Jenny Peterson-Klaus(Foundation for the National Institutes of Health), Ethan Cerami, Sacha Gnjatic(Mount Sinai Hospital), Chia‐Chi Chang(The University of Texas MD Anderson Cancer Center), Gerold Bongers(Mount Sinai Hospital), F. Stephen Hodi(Dana-Farber Cancer Institute), Rebecca A. Enos(Emmes (United States)), Howard Streicher(National Cancer Institute), J. Jack Lee(The University of Texas MD Anderson Cancer Center), Ming Tang(Army Medical University), Melissa Bowman(Emmes (United States)), Joyce E. Yu(Dana-Farber Cancer Institute), Cathy Rowe(Center for Information Technology), Mina Pichavant(Institute of Infection and Immunity)
Cited by 31
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k